Table 2.
Salivary SARS-CoV-2 load evolution for the CDCM and placebo groups (intention-to-treat analysis)
| CDCM | Placebo | p valuea | |
|---|---|---|---|
| Global | n = 88 | n = 88 | |
| Day 1 T1 | |||
| Median (IQR) | 4.05 (2.94–4.96) | 3.85 (2.97–5.08) | |
| Day 1 T2 | n = 88 (ID = 7) | n = 88 (ID = 5) | |
| Median (IQR) | 3.33 (2.29–4.23) | 3.60 (2.07–4.83) | |
| Median difference T1–T2 (IQR) | –0.38 (–1.39 to 0.00) | –0.15 (–0.97 to 0.33) | 0.036 |
| p valueb | <0.001 | 0.039 | |
| % decrease T1–T2 median (IQR) | –12.58% (–29.55% to –0.16%) | –6.74% (–21.16% to 10.44%) | |
| Day 1 T3 | n = 88 (ID = 11) | n = 88 (ID = 7) | |
| Median (IQR) | 3.08 (0–4.19) | 3.31 (1.18–4.75) | |
| Median difference T1–T3 (IQR) | –0.24 (–1.55 to 0.06) | –0.30 (–1.23 to 0.22) | 0.270 |
| p valueb | <0.001 | 0.002 | |
| % decrease T1–T3 median (IQR) | –10.67% (–37.30% to 3.25%) | –9.79% (–28.53% to 9.21%) | |
| Day 7 | n = 88 (ID = 14) | n = 88 (ID = 19) | |
| Median (IQR) | 0 (0–1.34) | 1.62 (0–1.70) | |
| Median difference T1–day 7 (IQR) | –2.07 (–4.03 to –0.50) | –2.11 (–3.35 to –0.86) | 0.388 |
| p valueb | <0.001 | <0.001 | |
| % decrease T1–day 7 median (IQR) | –58.62% (–100% to –34.36%) | –50.62% (–100% to –27.66%) | |
| Mean difference | –0.17 (90% CI –0.39 to 0.06) | ||
| MLM p valuec | 0.112 | ||
Abbreviations: CDCM, β-cyclodextrin-citrox mouthwash; ID, imputation data; IQR, interquartile range; MLM, mixed linear model; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Data are expressed in log10 copies/mL of saliva or in % for the % of variation calculated with values expressed in log10 copies/mL.
a
Mann–Whitney U test of the differences with a unilateral alternative hypothesis (H1 CDCM < Placebo).
b
Wilcoxon rank signed test of the differences.
c
Mixed linear model of the concentrations over time with a unilateral alternative hypothesis (H1 CDCM < Placebo).